What side effects are most commonly reported with Keytruda?
Keytruda (pembrolizumab) most often causes fatigue, rash, itching, muscle or joint pain, diarrhea, and nausea. These effects occur because the drug removes the brakes on the immune system, which can also attack healthy tissue. Most patients experience mild to moderate symptoms, but any new or worsening issue should be reported promptly to the care team.
When do serious immune-related side effects usually appear?
Serious reactions such as inflammation of the lungs (pneumonitis), liver (hepatitis), colon (colitis), kidneys (nephritis), or hormone-producing glands (endocrinopathies) can develop weeks to months after starting treatment. Early signs include shortness of breath, persistent cough, yellowing of skin or eyes, severe abdominal pain, dark urine, or unusual fatigue and weight changes.
What symptoms require immediate medical attention?
Seek urgent care for chest pain, severe shortness of breath, confusion, severe diarrhea or bloody stools, intense abdominal pain, sudden vision changes, or signs of infusion reactions such as fever, chills, or facial swelling. These can signal life-threatening complications that need steroids or treatment interruption.
How are these side effects typically managed?
Doctors often pause Keytruda and prescribe corticosteroids or other immunosuppressants until symptoms improve. Hormone replacement may be needed for thyroid, adrenal, or pituitary damage. Regular blood tests monitor liver, kidney, and thyroid function, and imaging checks for lung or bowel inflammation.
Are certain patients at higher risk for severe reactions?
People with pre-existing autoimmune diseases, prior severe reactions to checkpoint inhibitors, or those receiving Keytruda with other immunotherapies or chemotherapy tend to have higher rates of serious side effects. Close monitoring and dose adjustments are often required in these groups.
How does Keytruda’s safety profile compare with other PD-1 inhibitors?
Across studies, Keytruda shows a similar range of immune-related toxicities to nivolumab and cemiplimab, though rash and colitis appear slightly more frequent with Keytruda in some trials. The choice between agents usually hinges on approved indications, dosing schedule, and cost rather than major differences in side-effect frequency.
What long-term monitoring is recommended after stopping Keytruda?
Endocrine problems, especially thyroid and adrenal insufficiency, can persist or appear months after the last dose. Patients should continue periodic lab checks for at least a year post-treatment and report new fatigue, weight changes, or dizziness to their oncologist.